Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774718 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
A Phase 1 study of ALK Fusion-positive Solid or CNS Tumors, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 20
- Study locations
NCT04774718: Recruiting Phase 1 study of ALK Fusion-positive Solid or CNS Tumors, sponsored by Hoffmann-La Roche.
NCT04774718 is a Phase 1 study of ALK Fusion-positive Solid or CNS Tumors that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04774718, a Phase 1 study of ALK Fusion-positive Solid or CNS Tumors, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
Conditions Studied
Interventions
- DRUG Alectinib
Study Locations (20)
Other
- Beijing Children's Hospital, Capital Medical University - Beijing
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine - Shanghai
- Rigshospitalet - København Ø
- Centre Léon Bérard, Institut d?Hémato-Oncologie Pédiatrique - Lyon
- Hôpital de la Timone, Oncologie Pédiatrique - Marseille
- Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris - Paris
- Universitätsklinikum Heidelberg - Heidelberg
São Paulo
- Hospital de Cancer de Barretos - Barretos
- Graacc-Grupo de Apoio ao adolescente e a crianca com cancer - São Paulo
California
- Lucile Packard Children's Hospital - Palo Alto
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Michigan
- University of Michigan, C.S. Mott Children's Hospital - Ann Arbor
Minnesota
- Children's Minnesota - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2032-02-28 |
| Phase | Phase 1 |
What NCT04774718 shows while recruiting
NCT04774718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with ALK Fusion-positive Solid or CNS Tumors appearing as the primary indexed condition, and to 1 intervention - of which Alectinib is the first listed.
NCT04774718 names 20 study sites across 13 states, led by Other, São Paulo, California.
Frequently Asked Questions
What is clinical trial NCT04774718 about?
NCT04774718 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors". This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
What is the current status of trial NCT04774718?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-09-14. Estimated completion is 2032-02-28.
What conditions does trial NCT04774718 study?
This clinical trial studies the following conditions: ALK Fusion-positive Solid or CNS Tumors.
What interventions are being tested in trial NCT04774718?
The interventions under investigation include: Alectinib (DRUG).
Who is sponsoring clinical trial NCT04774718?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04774718 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04774718's enrollment target sits among peer trials
42 1106th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI